WCLC 2025 - Posters & ePosters-P2.08 .43 Perioperative Adebrelimab Plus Chemotherapy in Patients With Resectable Stage II-III NSCLC: 4-Year Update From a Phase 1b/3 Trial

P2.08 .43 Perioperative Adebrelimab Plus Chemotherapy in Patients With Resectable Stage II-III NSCLC: 4-Year Update From a Phase 1b/3 Trial

Back to course

Pdf Summary

This 4-year update reports on perioperative adebrelimab combined with chemotherapy in a phase 1b/3 trial involving patients with resectable stage II–III non-small cell lung cancer (NSCLC) without known EGFR/ALK driver mutations. The trial enrolled 37 patients who received neoadjuvant adebrelimab (an anti–PD-L1 monoclonal antibody) plus chemotherapy (nab-paclitaxel and carboplatin) over 3 cycles, followed by surgery and up to 16 cycles of adjuvant adebrelimab.<br /><br />Key eligibility included resectable stage II–III NSCLC, ECOG performance status 0–1, and no prior systemic therapy. After a median follow-up of 47 months, the study demonstrated sustained survival benefits with 4-year event-free survival (EFS) of 71.4%, disease-free survival (DFS) of 72.1%, and overall survival (OS) of 81.1%. These outcomes confirm the durable efficacy of perioperative chemoimmunotherapy in this setting.<br /><br />Safety outcomes were consistent with prior reports: 78.4% of patients experienced grade 3 treatment-related adverse events (mainly hematologic), and 27% had serious adverse events related to treatment. Importantly, there were no treatment-related deaths and no new safety signals identified.<br /><br />Prior phase 1b data had shown favorable surgical outcomes, including major pathological response (MPR) in 55.9% and pathological complete response (pCR) in 29.7% of patients. This updated long-term follow-up further supports that perioperative adebrelimab with chemotherapy is effective and tolerable, offering a meaningful survival advantage in resectable stage II–III NSCLC.<br /><br />The randomized, double-blind, placebo-controlled phase 3 portion of the trial is ongoing, with primary results expected soon. This multicenter trial underscores the potential of combining neoadjuvant chemoimmunotherapy with adjuvant immunotherapy to improve resection rates, eradicate micrometastasis, and reduce relapse risk in operable NSCLC.

Asset Subtitle

Yi-Long Wu

Meta Tag

Speaker Yi-Long Wu

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

adebrelimab

perioperative chemoimmunotherapy

non-small cell lung cancer

NSCLC stage II-III

neoadjuvant therapy

adjuvant therapy

event-free survival

pathological complete response

treatment-related adverse events

phase 1b/3 clinical trial